Oramed Pharmaceuticals Inc. Common Stock (ORMP)

FairStock Score: 87/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $4 million in annual free cash flow (2.5% yield on market cap)
• High return on equity of 37.1% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.00, providing financial flexibility
• Superior net profit margin of 500.5% indicating pricing power and operational efficiency
• Attractive 6.4% dividend yield providing steady income returns

Concerns

• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Oramed Pharmaceuticals Inc. Common Stock is a micro-cap healthcare company valued at $156 million. The business generates $2 million in annual revenue with a 500.5% net margin and $4 million in free cash flow. From a quality standpoint, Oramed shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and Altman Z-Score of 2.8 in the grey zone. On valuation, the stock is deeply undervalued on a P/E basis at 2.6x, with offers a 71% margin of safety vs Graham Number of $13. Growth dynamics show profit growth of 198.2%. The 6.4% dividend yield adds an income component for patient holders. Our composite FairStock Score of 87/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

The market underappreciates Oramed's consistent 37% ROE at just 3x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $4 million in annual free cash flow (2.5% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer